Exclusive Summary

• Features an innovative 1ml:50mg high-concentration formulation that delivers the standard daily dose for ART luteal support in a single vial, reducing injection volume by up to 80% and significantly minimizing injection site pain.
• Built on robust evidence and compliance, aligning perfectly with ESHRE 2020 guidelines while holding PIC/S GMP certification (with US FDA GMP inspection targeted for 2026), ensuring streamlined global market access.
• Offers massive commercial upside in the globally expanding $36 Billion ART market, backed by a striking 30-60% pricing advantage over US/EU equivalents that clearly guarantees high margins for overseas distributors.

Asset Materials

Contact Us for Full Materials